| abstract |
The present invention relates to the use of diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an antigen adjuvant in fusion proteins and fused target proteins such as an HEV capsid protein or an influenza virus M2 protein or an immunogenic fragment thereof for enhancing immunogenicity Lt; / RTI > Also provided is a method for enhancing the immunogenicity of a target protein, comprising fusion expression of the target protein with CRM197 or a fragment thereof to form a fusion protein. Also provided is a fusion protein comprising the CMR197 or a fragment thereof and a target protein, wherein the CRM197 or fragment thereof increases the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct comprising the nucleic acid and a vector, and a host cell comprising the nucleic acid. |